Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 13/20 | 0.41 |
| ▸ | ADH1C | P00326 | 10/20 | 0.41 |
| ▸ | ADH1B | P00325 | 5/20 | 0.41 |
| ▸ | ADH4 | P08319 | 3/20 | 0.41 |
| ▸ | ADH7 | P40394 | 3/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11734533 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| Cyclononanecarbaldehyde SCHEMBL1920808 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL11341547 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| Cyclopentanecarbaldehyde SCHEMBL14575123 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL493755 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL3036861 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| Cycloheptane Carbaldehyde SCHEMBL95620 | 1.00 | — | — | |
| SCHEMBL59918 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| Cycloundecane Carbaldehyde SCHEMBL1901240 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL3027683 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160127-B | Method for preparing long carbon chain dibasic acid through co-oxidation reaction | 中国天辰工程有限公司 | 2024-06-11 | — | — | CN | claimed |
| US-20140162937-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | NORTHERN ANTIBIOTICS LTD. (FI) | 2014-06-12 | — | — | US | claimed |
| US-8680234-B2 | Polymyxin derivatives and uses thereof | NORTHERN ANTIBIOTICS OY (FI) | 2014-03-25 | — | — | US | claimed |
| US-8329645-B2 | Polymyxin derivatives and uses thereof | NORTHERN ANTIBIOTICS LTD. (FI) | 2012-12-11 | — | — | US | claimed |
| US-8138248-B2 | Method to improve cold flow resistance of polymers | BRIDGESTONE CORPORATION (JP) | 2012-03-20 | — | — | US | claimed |
| US-20100292136-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | NORTHERN ANTIBIOTICS OY (FI) | 2010-11-18 | — | — | US | claimed |
| US-20100004361-A1 | METHOD TO IMPROVE COLD FLOW RESISTANCE OF POLYMERS | BRIDGESTONE CORPORATION (JP) | 2010-01-07 | — | — | US | claimed |
| US-20090215677-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | NORTHERN ANTIBIOTICS LTD. (FI) | 2009-08-27 | — | — | US | claimed |
| US-4181810-A | FROM THE 2-SUBSTITUTED ETHANAL AND FORMALDEHYDE USING AN ACID ION EXCHANGER; HYDROGENATION OF REACTION PRODUCT | BAYER AKTIENGESELLSCHAFT (DE) | 1980-01-01 | — | — | US | claimed |
| US-4020059-A | Process for preparing tertiary amines | NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JA) | 1977-04-26 | — | — | US | claimed |
| US-20250123289-A1 | Derivatization Reagent, Derivatization Reagent Kit, and Method for Improving Sensitivity of Nitrogen-Containing Compound in Mass Spectrometry | JEOL LTD. (JP) | 2025-04-17 | — | — | US | disclosed |
| EP-4538710-A1 | DERIVATIZATION REAGENT, DERIVATIZATION REAGENT KIT, AND METHOD FOR IMPROVING SENSITIVITY OF NITROGEN-CONTAINING COMPOUND IN MASS SPECTROMETRY | JEOL Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| CN-119804875-A | Derivatization reagent, derivatization kit, and method for improving sensitivity of nitrogen-containing compound in mass spectrometry | 日本电子株式会社 | 2025-04-11 | — | — | CN | disclosed |
| CN-116020552-B | Butadiene cyclization trimerization catalyst, preparation method and application thereof | 中国石油化工股份有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-115160127-B | Method for preparing long carbon chain dibasic acid through co-oxidation reaction | 中国天辰工程有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-4181810-A | FROM THE 2-SUBSTITUTED ETHANAL AND FORMALDEHYDE USING AN ACID ION EXCHANGER; HYDROGENATION OF REACTION PRODUCT | BAYER AKTIENGESELLSCHAFT (DE) | 1980-01-01 | — | — | US | disclosed |
| US-4153606-A | Process for the production of thiazoline-(3) compounds | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1979-05-08 | — | — | US | disclosed |
| US-4081459-A | Trioxa-1, 5, 7 spiro [2,5] octanes and their method of preparation | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1978-03-28 | — | — | US | disclosed |
| US-4020059-A | Process for preparing tertiary amines | NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JA) | 1977-04-26 | — | — | US | disclosed |
| US-3931208-A | Process for the production of thiazolines-(3) | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215677-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | C5, C9, C3AR1 | ADH1A 4879/4885ADH1C 4883/4885ADH1B 4781/4885 |
| US-20140162937-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | SLC11A2, TLR2, TLR5 | ADH1A 4872/4885ADH1C 4883/4885ADH1B 4804/4885 |
| US-20100292136-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | C5, C9, C3AR1 | ADH1A 4879/4885ADH1C 4883/4885ADH1B 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.